OraQuick Rapid HCV antibody test was CP-868596 utilized to provide point of care HCV screening with results

available in 20-40 minutes. All patients completed a questionnaire prior to endoscopy regarding risk factors and exposures. Patients who tested positive for HCV were contacted for further testing and possible therapy. Results: HCV screening was offered to 254 patients and 220 agreed to be tested. Thirty-four patients declined testing (14%). The majority (62%) who declined were women. Two patients were found to be hepatitis C positive (1%); however both were already known to have hepatitis C. No new diagnoses of chronic hepatitis were made. Traditional risk factors for HCV transmission were prevalent, including illicit drug use (21.4%), acupuncture (19.5%), STD’s (12.3%), tattoos (8.2%), and IVDU (2.3%). There was a Caucasian predominance to the cohort of 62%. Point of care testing Small molecule library and counseling did

not affect the work-flow or efficiency of the endoscopy center. Prior to initiation of this study, average patient time after the nurse’s interview to patient discharge was 1 hour 52 minutes. During the enrollment and HCV testing period the patient time to proceed through endoscopy was largely unchanged at 1 hour 47 minutes. Conclusions This prospective study demonstrates that it is possible to test patients for viral hepatitis during routine colonoscopy and endoscopy in an efficient and time effective manner. Earlier studies documented a 1% new diagnosis rate, however despite prevalent traditional HCV risk factors in our study cohort we had no new diagnoses at this interval analysis. Point of care testing allows for high rates of patient acceptance. Also, testing did not delay workflow at the endoscopy center. Given recent CDC recommendations for birth cohort screening for HCV, gastroenterologists MCE should strongly consider PoC testing in non-traditional

patient interactions such as endoscopy. Disclosures: The following people have nothing to disclose: Raja Taunk, Daniel I. Zapata, Jennifer Stone, Victoria Menashy, llan Weisberg Introduction: Progressive liver damage due to hepatitis C virus infection is a major cause of co-morbidity in haemophilia patients. The need for accurate diagnostic tools for assessing the extent of liver fibrosis is high in these patients. The aim of this study was to investigate the additional value of the enhanced liver fibrosis (ELF) test combining hyaluronic acid, procollagen-III-amino terminal peptide and tissue inhibitor of metalloproteinase-1 compared to transient elastography (TE). Methods: We evaluated the ELF score in 58 HCV-infected haemophilia patients on the ADVIA Centaur XP (Siemens). TE was performed by using the FibroScan (Echosens, Paris, France). In 15 patients (25.